TMC278-C204: TMC278 in Treatment Naive HIV-1 Infected Subjects

This study has been completed.

Sponsor:

Information provided by:

Tibotec Pharmaceuticals, Ireland

ClinicalTrials.gov Identifier:

NCT00110305

First received: May 5, 2005

Last updated: August 7, 2012

Last verified: August 2012

History of Changes

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Study Status:	This study has been completed.
Study Completion Date:	December 2011
Primary Completion Date:	December 2011 (Final data collection date for primary outcome measure)

No publications provided by Tibotec Pharmaceuticals, Ireland

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Pozniak AL, Morales-Ramirez J, Katabira E, Steyn D, Lupo SH, Santoscoy M, Grinsztejn B, Ruxrungtham K, Rimsky LT, Vanveggel S, Boven K; TMC278-C204 Study Group. Efficacy and safety of TMC278 in antiretroviral-naive HIV-1 patients: week 96 results of a phase IIb randomized trial. AIDS. 2010 Jan 2;24(1):55-65.

To Top